Chong Kun Dang Pharmaceutical Corp (185750) Fair Value & Analysis
Healthcare · KR · Market cap 900B KRW
Fair value as of: Jul 24, 2026
From 14 valuation models · updated 17 days ago
Share price +1.3% over the past month.
Below-average quality, screening 42% undervalued on our models.
What matters now
- The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain.
- The price is below even our cautious bear case (75,002 KRW). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.
How to read this chart
60‑month range 60,674 KRW – 153,017 KRW · fair‑value band 75,002 KRW – 125,004 KRW · the 70,500 KRW price screens below the 100,003 KRW fair value. Dashed = 300-day average. As of Jul 24, 2026.
Analysis
Chong Kun Dang Pharmaceutical Corp (185750) currently trades at 70,500 KRW, while our model-based Fair Value estimate is 100,003 KRW, implying the stock looks roughly 41.9% undervalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Chong Kun Dang Pharmaceutical Corp generated revenue of 860B KRW at a net margin of 6.1%. Revenue grew 11.7% year over year. It earns a return on equity of 14.5%. Net debt stands at 142B KRW. Fundamentals as of Jul 24, 2026
Our scenario range runs from 75,002 KRW (bear case) to 125,004 KRW (bull case); at 70,500 KRW, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 34% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 42%, 185750 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Growth Earnings (115,734 KRW) versus Earnings-Based (41,354 KRW). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 24, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health …
Full company description
Chong Kun Dang Pharmaceutical Corp. manufactures, markets, and sells medicines in South Korea and internationally. It offers prescription drugs for anti-hypertension, anti-hyperlipidaemia, and anti-diabetics, as well as immunosuppressants; over-the-counter medicines; and consumer health products, such as insecticides and hair dye products, as well as health supplements. The company was founded in 1941 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chong Kun Dang Pharmaceutical Corp reported revenue of 1.7T KRW in FY2025 versus 1.3T KRW in FY2021, a compound +5.9%/yr. Reported net income was 77.5B KRW in FY2025, compounding +16.1%/yr from FY2021.
Watch 185750: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 626 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare Chong Kun Dang Pharmaceutical Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chong Kun Dang Pharmaceutical Corp (185750) overvalued or undervalued?
What is the fair value of 185750?
What is the quality score of 185750?
What is the revenue of Chong Kun Dang Pharmaceutical Corp (185750)?
What is the net profit margin of 185750?
Does Chong Kun Dang Pharmaceutical Corp pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Chong Kun Dang Pharmaceutical Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.